Morgan Stanley
BXRX

Morgan Stanley’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Morgan Stanley’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed – – 8076
2023
Q3 		$0 Hold
1
– – ﹤0.01% 7866
2023
Q2 		$1 Hold
1
– – ﹤0.01% 7651
2023
Q1 		$2 Sell
1
-1
-50% -$3 ﹤0.01% 7699
2022
Q4 		$6 Sell
2
-133
-99% -$796 ﹤0.01% 7829
2022
Q3 		$1K Buy
135
+113
+514% +$2.63K ﹤0.01% 7664
2022
Q2 		$1K Sell
22
-11
-33% -$514 ﹤0.01% 7761
2022
Q1 		$2K Buy
+33
New +$6.09K ﹤0.01% 7813
2021
Q4 		– Hold
0
– – – 8325
2021
Q3 		– Sell
-259
Closed -$225K – 8154
2021
Q2 		$276K Buy
259
+257
+12,850% +$336K ﹤0.01% 5853
2021
Q1 		$3K Hold
2
– – ﹤0.01% 7241
2020
Q4 		$3K Sell
2
-2
-50% -$4.09K ﹤0.01% 6875
2020
Q3 		$17K Sell
4
-2
-33% -$9.05K ﹤0.01% 6125
2020
Q2 		$35K Buy
6
+3
+100% +$14.4K ﹤0.01% 5814
2020
Q1 		$11K Sell
3
-9
-75% -$85K ﹤0.01% 6002
2019
Q4 		$120K Buy
+12
New +$102K ﹤0.01% 5592

Morgan Stanley's BXRX Position: Q4 2023 in Review

Morgan Stanley sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 1 share.

Morgan Stanley first reported a position in BXRX in Q4 2019 and held it in 14 quarters. The position peaked at $276K in Q2 2021. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.

  • Morgan Stanley reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 1 Baudax Bio, Inc. Common Stock share in Q4 2023.
  • Morgan Stanley first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
  • Morgan Stanley's Baudax Bio, Inc. Common Stock position peaked at $276K in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.